Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06912763 · ClinicalTrials.gov registry record · Phase 2

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

A Phase 2 study of Lymphedema and Fibrosis, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
250
Enrollment target
1
Study location

NCT06912763: Recruiting Phase 2 study of Lymphedema and Fibrosis, sponsored by M.D. Anderson Cancer Center.

NCT06912763 is a Phase 2 study of Lymphedema and Fibrosis that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 250 participants, below the 9,292-participant average among 34 other Lymphedema trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06912763, a Phase 2 study of Lymphedema and Fibrosis, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
250 participants
Enrollment target
1
Study location

Study Summary

To find out if adding medication can help treat or prevent lymphedema and/or fibrosis related to radiation therapy, in survivors of head and neck cancer. Researchers will compare these drugs to find the most effective therapy for preventing or limiting these side effects.

Primary Outcome

Incidence of Adverse of Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events

Interventions

  • OTHER Standard of Care (SOC)
  • DRUG Pravastatin (drug)
  • DRUG Pentoxifylline
  • DRUG ketoprofen
  • DRUG Pirfenidoneone

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2025-08-08
Est. Completion 2033-03-01
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What NCT06912763 shows while recruiting

NCT06912763 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 9,292-participant average among 34 other Lymphedema trials with a reported enrollment target (97% lower).

The record links to 4 conditions, with Lymphedema appearing as the primary indexed condition, and to 5 interventions - of which Standard of Care (SOC) is the first listed.

NCT06912763 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06912763 about?

NCT06912763 is a clinical study titled "Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)". To find out if adding medication can help treat or prevent lymphedema and/or fibrosis related to radiation therapy, in survivors of head and neck cancer. Researchers will compare these drugs to find the most effective therapy for preventing or limiting these side effects.

What is the current status of trial NCT06912763?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2025-08-08. Estimated completion is 2033-03-01.

What conditions does trial NCT06912763 study?

This clinical trial studies the following conditions: Lymphedema, Fibrosis, Head Neck Cancer, Fibrosis Syndrome.

What interventions are being tested in trial NCT06912763?

The interventions under investigation include: Standard of Care (SOC) (OTHER), Pravastatin (drug) (DRUG), Pentoxifylline (DRUG), ketoprofen (DRUG), Pirfenidoneone (DRUG).

Who is sponsoring clinical trial NCT06912763?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06912763 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lymphedema

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06912763's enrollment target sits among peer trials

250 11th of 34 higher than 24 of 34 other Lymphedema trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lymphedema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06912763, the US trial registry maintained by the National Library of Medicine. NCT06912763 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.